Neuronal degeneration in striatal transplants and Huntington's disease: Potential mechanisms and clinical implications

Brain

Volumn 134, Issue 3, 2011, Pages 641-652

  Cicchetti, Francesca ^a,b   Soulet, Denis ^a,b   Freeman, Thomas B ^c,d,e  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e NONE   (United States)

Author keywords

Huntington's disease; neurosurgery; transplantation

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HUNTINGTIN;

ARTICLE; BRAIN DEPTH STIMULATION; CELL THERAPY; CELL TRANSPLANTATION; CELLULAR IMMUNITY; CORPUS STRIATUM; CYTOTOXICITY; DISEASE TRANSMISSION; GLIA CELL; GRAFT SURVIVAL; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOREACTIVITY; MICROGLIA; NERVE CELL DEGENERATION; NERVE GRAFT; NERVE TRANSPLANTATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION;

ANIMALS; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL; NERVE DEGENERATION; NEUROGLIA; SIGNAL TRANSDUCTION;

EID: 79952163901     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq328     Document Type: Article

References (100)

1. Arzberger T, Krampfl K, Leimgruber S, Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease: an in situ h (Pubitemid 27465027)
2. Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 2000;161:194-202. (Pubitemid 30136541)
3. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303-9.
4. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002;125:1908-22.
5. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008;205:1869-77.
6. Braak H, Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med 2008;14:483-485. (Pubitemid 351655198)
7. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009;106:22480-5.
8. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010;285:10653-61.
9. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008;9:741-5.
10. Brundin P, Karlsson J, Emgard M, Schierle GS, Hansson O, Petersen A, et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant 2000;9:179-95. (Pubitemid 30252685)
11. Campbell K, Kalen P, Wictorin K, Lundberg C, Mandel RJ, Bjorklund A. Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents. Neuroscience 1993;53:403-15. (Pubitemid 23101324)
12. Cardoso F. Huntington disease and other choreas. Neurol Clin 2009;27:719-36, vi.
13. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007;27:8011-22. (Pubitemid 47173327)
14. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-33. (Pubitemid 47343795)
15. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Role of serotonin neurons in the induction of levodopa-and graft-induced dyskinesias in Parkinson's disease. Mov Disord 2010;25(Suppl. 1): S174-9.
16. Chesebro B, Race B, Meade-White K, Lacasse R, Race R, Klingeborn M, et al. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 2010;6: e1000800.
17. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008;28:3277-90. (Pubitemid 351469331)
18. Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci USA 2009;106:12483-8.
19. Cooper O, Astradsson A, Hallett P, Robertson H, Mendez I, Isacson O. Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol 2009;256(Suppl. 3):310):310-6.
20. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976;263:244-6.
21. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, Schultz C, et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 2006;9:1302-11. (Pubitemid 44454272)
22. Dobrossy MD, Dunnett SB. Striatal grafts alleviate deficits in response execution in a lateralised reaction time task. Brain Res Bull 1998;47:585-93. (Pubitemid 29115371)
23. Dunnett SB. Functional repair of striatal systems by neural transplants: evidence for circuit reconstruction. Behav Brain Res 1995;66:133-42.
24. Dunnett SB, Nathwani F, Bjorklund A. The integration and function of striatal grafts. Prog Brain Res 2000;127:345-80. (Pubitemid 35461267)
25. Dunnett SB, Carter RJ, Watts C, Torres EM, Mahal A, Mangiarini L, et al. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp Neurol 1998;154:31-40. (Pubitemid 28553564)
26. Flott-Rahmel B, Falter C, Schluff P, Fingerhut R, Christensen E, Jakobs C, et al. Nerve cell lesions caused by 3-hydroxyglutaric acid: a possible mechanism for neurodegeneration in glutaric acidaemia I. J Inherit Metab Dis 1997;20:387-90. (Pubitemid 27354622)
27. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9. (Pubitemid 32204988)
28. Freeman TB, Brundin P. Important aspects of surgical methodology for transplantation in Parkinson's disease. London: England Springer; 2006.
29. Freeman TB, Cicchetti F, Bachoud-Levi AC, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011;227:1-9.
30. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, et al. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA 2000;97:13877-82.
31. Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlonga CV, et al. Human fetal tissue transplantation. AANS Publications Committee; 1998.
32. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995;38:379-88.
33. Funk CB, Prasad AN, Frosk P, Sauer S, Kolker S, Greenberg CR, et al. Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort. Brain 2005;128:711-22. (Pubitemid 40516910)
34. Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, et al. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 1999;19:1189-202. (Pubitemid 29088902)
35. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918-34.
36. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006;125:1179-91. (Pubitemid 43866195)
37. Greene PE, Fahn S. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus 2002;13: e3.
38. Gu X, André VM, Cepeda C, Li SH, Li XJ, Levine MS, et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener 2007;2:1-11.
39. Gu X, Li C, Wei W, Lo V, Gong S, Li SH, et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005;46:433-44. (Pubitemid 40616887)
40. Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 1999;14:448-55. (Pubitemid 30011655)
41. Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-8. (Pubitemid 34742975)
42. Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008;33:232-7.
43. Hauser RA, Sandberg PR, Freeman TB, Stoessl AJ. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002;58:1704, author reply. (Pubitemid 34602915)
44. Hebb MO, Denovan-Wright EM, Robertson HA. Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats. Faseb J 1999;13:1099-106. (Pubitemid 29249736)
45. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382-97.
46. Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004;127:505-16. (Pubitemid 38295468)
47. Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007;68:2093-8. (Pubitemid 46912127)
48. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 1998;149:97-108. (Pubitemid 28091019)
49. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008a; 14:504-6. (Pubitemid 351655212)
50. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord 2008b; 23:2303-6.
51. Kordower JH, Styren S, Clarke M, DeKosky ST, Olanow CW, Freeman TB. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997;6:213-9. (Pubitemid 27225172)
52. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-24.
53. Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996;370:203-30. (Pubitemid 26227146)
54. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006;96:1121-9.
55. Levine MS, Cepeda C, Andre VM. Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease. Neuron 2010;65:145-7.
56. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-3. (Pubitemid 351655211)
57. Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, et al. Characterization of Lewy body pathology in 12-and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010;25:1091-6.
58. Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005;14:713-24. (Pubitemid 40309596)
59. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 2001;8:807-21. (Pubitemid 33055597)
60. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990;247:574-7.
61. Mayer E, Brown VJ, Dunnett SB, Robbins TW. Striatal graft-associated recovery of a lesion-induced performance deficit in the rat requires learning to use the transplant. Eur J Neurosci 1992;4:119-26.
62. Mendez I, Dagher A, Hong M, Gaudet P, Weerasinghe S, McAlister V, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 2002;96:589-96. (Pubitemid 34230217)
63. Mendez I, Sanchez-Pernaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005;128:1498-510. (Pubitemid 41373670)
64. Mendez I, Vinuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008;14:507-9. (Pubitemid 351655215)
65. Nakao N, Ogura M, Nakai K, Itakura T. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 1999;88:469-77. (Pubitemid 28480007)
66. Nguyen MD, Julien JP, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci 2002;3:216-27. (Pubitemid 135706591)
67. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-8. (Pubitemid 40746128)
68. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 2009;106:12571-2.
69. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14. (Pubitemid 37072046)
70. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325-40. (Pubitemid 36071510)
71. Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2010;37:356-61.
72. Peschanski M, Cesaro P, Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995;68:273-85.
73. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 1999;157:1-18. (Pubitemid 29226865)
74. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;2:1137-40. (Pubitemid 30126374)
75. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2:38ra46.
76. Raju D, Smith Y. Differential Localization of Vesicular Glutamate Transporters 1 and 2 in the Rat Striatum. New York: Springer Science and Business Media; 2005. p. 601-10.
77. Redmond DE Jr, Vinuela A, Kordower JH, Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis 2008;29:103-16. (Pubitemid 350186113)
78. Reuter I, Tai YF, Pavese N, Chaudhuri KR, Mason S, Polkey CE, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry 2008;79:948-51.
79. Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002;73:678-85. (Pubitemid 35448852)
80. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001;60:161-72. (Pubitemid 32172419)
81. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 2010;90:230-45.
82. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005;171:1001-12.
83. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006;49:489-502. (Pubitemid 43221886)
84. Singhrao SK, Thomas P, Wood JD, MacMillan JC, Neal JW, Harper PS, et al. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 1998;150:213-22. (Pubitemid 28231952)
85. Sirinathsinghji DJ, Dunnett SB, Isacson O, Clarke DJ, Kendrick K, Bjorklund A. Striatal grafts in rats with unilateral neostriatal lesions-II. In vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 1988;24:803-11.
86. Sirinathsinghji DJ, Heavens RP, Torres EM, Dunnett SB. Cholecystokinin-dependent regulation of host dopamine inputs to striatal grafts. Neuroscience 1993;53:651-63. (Pubitemid 23114554)
87. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005;102:11402-7. (Pubitemid 41153832)
88. Soderstrom KE, Meredith G, Freeman TB, McGuire SO, Collier TJ, Sortwell CE, et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors. Neurobiol Dis 2008;32:229-42.
89. Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, et al. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 2007;27:12908-15. (Pubitemid 350159593)
90. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007;72:148-51. (Pubitemid 46389550)
91. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007;85:2059-70. (Pubitemid 47172138)
92. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-77. (Pubitemid 16196286)
93. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 2009;29:3974-80.
94. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet 2008;17:2738-51.
95. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog Neurobiol 1992;38:611-39.
96. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009;1792:688-702.
97. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005;28:86-92. (Pubitemid 40178925)
98. Xu ZC, Wilson CJ, Emson PC. Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J Neurophysiol 1991;65:477-93.
99. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002;33:849-60. (Pubitemid 34246352)
100. Zuchner T, Brundin P. Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ 2008;15:435-42. (Pubitemid 351267294)